Skip to main content

Table 2 ORs and 95 % CIs for NHL by markers of HCV and HBV. Italy, 1999–2014

From: Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy

  NHL Controls  
  N (%) N (%) OR (95 % CI)a
HCV 571 1004  
 Anti-HCV- 492 (86.2) 940 (93.6) 1b
 Anti-HCV+ 79 (13.8) 64 (6.4) 2.39 (1.66–3.43)
   HCV RNA -c 14 (2.5) 27 (2.7) 0.98 (0.50–1.92)
   HCV RNA + 63 (11.1) 35 (3.5) 3.51 (2.25–5.47)
HBVd 570 997  
 HBsAg-/anti-HBs-/anti-HBc- 359 (63.0) 609 (61.1) 1b
 HBsAg-/anti-HBs+/anti-HBc+ 90 (15.8) 179 (18.0) 0.78 (0.58–1.06)
 HBsAg-/anti-HBs+/anti-HBc- 53 (9.3) 122 (12.2) 0.87 (0.59–1.29)
 HBsAg-/anti-HBs-/anti-HBc+ 47 (8.2) 70 (7.0) 1.10 (0.73–1.65)
 HBsAg+ 21 (3.7) 17 (1.7) 1.95 (1.00–3.81)
  1. NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval
  2. aEstimated using unconditional logistic regression models adjusted for gender, age, study center, years of education, and place of birth; bReference category; cInformation on HCV RNA was missing for 2 cases and 2 controls; d1 case and 7 controls without complete information on all HBV markers were excluded